March 19, 2018 12:20 PM ET


Company Overview of Karuna Pharmaceuticals Inc

Company Overview

Karuna Pharmaceuticals Inc., a clinical-stage pharmaceutical company, targets muscarinic receptors for the treatment of CNS disorders. The company offers KarXT that targets the muscarinic system for the treatment of schizophrenia and is composed of xanomeline, a novel clinical-stage muscarinic acetylcholine receptor agonist (activator); and trospium chloride, an FDA-approved muscarinic receptor antagonist (blocker) that has been shown not to enter the central nervous system. Its KarXT controls psychosis. The company was incorporated in 2009 and is based in Boston, Massachusetts. Karuna Pharmaceuticals Inc. operates as a subsidiary of PureTech Health plc.

501 Boylston Street

Suite 6102

Boston, MA 02116

United States

Founded in 2009





Key Executives for Karuna Pharmaceuticals Inc

Founder, Chief Executive Officer, President and Director
Age: 64
Chief Medical Officer
Chief Clinical Advisor
Compensation as of Fiscal Year 2017.

Karuna Pharmaceuticals Inc Key Developments

Karuna Pharmaceuticals Announces Positive Results from Tolerability Proof-Of-Concept Study of KarXT

Karuna Pharmaceuticals announced positive results from a tolerability proof-of-concept study of its proprietary product, KarXT. In the study, KarXT (xanomeline plus trospium chloride), which is being developed as a novel antipsychotic for schizophrenia and Alzheimer's disease, was found to be generally well-tolerated and have superior tolerability to xanomeline alone. Based on these positive safety results and previous efficacy data on xanomeline, Karuna intends to initiate a Phase 2 clinical trial of KarXT in 2017. KarXT was shown to reduce the incidence of prespecified cholinergic adverse events by a statistically significant and clinically meaningful extent (46% p=0.016). KarXT combines xanomeline, a novel clinical-stage muscarinic acetylcholine receptor agonist, with trospium chloride, a muscarinic antagonist, and is being developed to selectively target muscarinic receptors in the CNS. Exclusively licensed to Karuna, xanomeline has demonstrated robust efficacy in reducing psychosis in both schizophrenia and Alzheimer's disease in previous studies, however, it has been associated with side effects that have limited its development. The results of the KarXT proof-of-concept study indicate that the addition of trospium chloride results in improved tolerability of xanomeline. Based on these positive safety results and previous efficacy data on xanomeline, Karuna intends to initiate a Phase 2 clinical trial of KarXT in 2017.

Karuna Pharmaceuticals Announces Dosing of the First Subject in Tolerability Proof-Of-Concept Study of its Proprietary Lead Product KarXT

Karuna Pharmaceuticals announced the dosing of the first subject in a tolerability proof-of-concept study of its proprietary lead product KarXT (xanomeline plus trospium chloride). The study, which will be conducted in up to 70 healthy individuals, aims to evaluate the tolerability of KarXT compared to xanomeline alone. Exclusively licensed to Karuna, xanomeline is a novel, muscarinic acetylcholine receptor agonist that has demonstrated robust efficacy in treating schizophrenia and psychosis in Alzheimer’s disease; however, it has also been associated with tolerability issues that have hindered its development. In a double-blind, placebo-controlled, monotherapy study in people with schizophrenia, a statistically significant, 24-point reduction over placebo was observed on the Positive and Negative Syndrome Scale (PANSS), a standard tool used to measure symptom severity in people with schizophrenia. By selectively targeting muscarinic receptors in the CNS with the KarXT approach, Karuna aims to reduce the peripheral cholinergic side effects previously seen with xanomeline alone. The randomized, double-blind, multiple-dose study will dose up to 70 healthy volunteers aged 18 to 60 for in-clinic treatment over the course of nine days. Following a two-day run-in period with trospium alone, subjects will receive xanomeline with either trospium chloride or placebo. Top-line results are expected by the end of 2016.

Karuna Pharmaceuticals Appoints Atul Pande to its Board

Karuna Pharmaceuticals announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development. Dr. Pande has more than two decades of experience in drug development. Dr. Pande is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. Dr. Pande has been active in the development of multiple important central nervous system drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer's and Parkinson's diseases.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Karuna Pharmaceuticals Inc, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at